Furaprevir
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Furaprevir
- Molecular weight
- 897.06
- Structure (SMILES)
- CC(C)Oc1ccc(-c2nc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)c3oc4ccccc4c3n2)cc1
- dag181 200 mg plus tg 2349 400 mg
- furaprevir
- Furaprevir
- furaprevir [INN]
- Furaprevir [WHO-DD]
- Furaprevir capsule (MAD)
- Furaprevir capsule (SAD)
- furaprevir inn
- furaprevir who dd
- tg 2349
- Tg-2349
- TG-2349
- CAS registry numbers
- 1435923-88-8
- ChEMBL ID
- CHEMBL4297647
- InChIKey
- GZRNOYTVBWWFLJ-NTPALUMKSA-N
- PubChem compound IDs
- 51037069
- FDA ingredient codes (UNII)
- 0UMM44REU9
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -vir
- Mechanism
- Hepatitis C virus serine protease, NS3/NS4A inhibitor
- Action type
- Inhibitor
- Target
- Hepatitis C virus serine protease, NS3/NS4A
- Protein identifier
- A3EZI9
- Mechanism
- Hepatitis C virus serine protease, NS3/NS4A inhibitor
- Action type
- Inhibitor
- Target
- Hepatitis C virus serine protease, NS3/NS4A
- Protein identifier
- D2K2A8
Open Targets mechanisms
- Mechanism
- Hepatitis C virus serine protease, NS3/NS4A inhibitor
- Action type
- Inhibitor
- Target
- Hepatitis C virus serine protease, NS3/NS4A
- Condition
- Hepatitis C
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
- Condition
- Hepatitis C, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004220
- Subject identifier
- D019698
- Condition identifier
- EFO_0003047
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004220
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005231
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005354
- Highest recorded phase
- 2
- NCT01523990
- NCT02340962
- NCT04155515
- Hydrogen bond acceptors
- 12
- Hydrogen bond donors
- 3
- Polar surface area
- 208.36
- Calculated partition coefficient (ALogP)
- 6.61
- Calculated partition coefficient (XLogP)
- 7.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 3
- Rotatable bonds
- 10
- Heavy atoms
- 64
- Molecular formula
- C47H56N6O10S
- Monoisotopic mass
- 896.37786318
- Natural product
- Yes
- Recorded assays
- 8
- Active assays
- 8
Active assay types
- Confirmatory
Related records
Trials (28)
- A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis B
- A Phase I Study of DDN-A-0101 in Healthy Volunteers and Elder People
- A Phase I Study of RC1416 Injection
- A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
- A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of THDBH120 Injection in Healthy Subjects
- A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
- A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
- A Study to Evaluate the Safety of K-755 in Healthy Volunteers
- A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients
- A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects
- A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects
- A Study to Find a Suitable Dose of Exl-111 for Further Research
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001
- BnH-015B Clinical Trial in Moderate Alzheimer's Disease
- EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)
- Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
- Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes
- Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy Subjects
- Prevention of Seasonal Affective Disorder
- Safety and Pharmacokinetics of Oral Controlled-ileocolonic-release Nicotinamide (CICR-NAM)
In development for (2)
- Chronic hepatitis C virus infection Phase 2
- Hepatitis C virus infection Phase 3